Results 81 to 90 of about 37,077 (282)
Experimental Hematology & Oncology, 2017 HER2-targeted immunotherapy consists of monoclonal antibodies (e.g. trastuzumab, pertuzumab), bispecific antibodies (e.g. MM-111, ertumaxomab) and activated T cells armed with anti-HER2 bispecific antibody (HER2Bi-aATC). Trastuzumab is a classic drug for
Shengnan Yu +6 more
doaj +1 more source
Advanced Science, EarlyView.This study identifies TOPK as a dual‐function target in gastric cancer: it drives tumor cell proliferation and migration, and under IFN‐γ stimulation, phosphorylates eIF4F complex component eIF4A1 to enhance STAT1 mRNA translation, thereby promoting PD‐L1/IDO1‐mediated tumor immunometabolic evasion.
Junbing Chen +16 more
wiley +1 more source
mAbs, 2022 As the current biotherapeutic market is dominated by antibodies, the design of different antibody formats, like bispecific antibodies, is critical to the advancement of the field.
Monica L. Fernández-Quintero +5 more
doaj +1 more source
CXCL12 retargeting of an adenovirus vector to cancer cells using a bispecific adapter [PDF]
, 2016 Ad vectors are promising delivery vehicles for cancer therapeutic interventions. However, their application is limited by promiscuous tissue tropism and hepatotoxicity. This limitation can be avoided by altering the native tropism of Ads so that they can
Bhatia, Shilpa +4 more
core +3 more sources
Bispecific antibodies: design, therapy, perspectives
Drug Design, Development and Therapy, 2018 Antibodies (Abs) containing two different antigen-binding sites in one molecule are called bispecific. Bispecific Abs (BsAbs) were first described in the 1960s, the first monoclonal BsAbs were generated in the 1980s by hybridoma technology, and the first article describing the therapeutic use of BsAbs was published in 1992, but the number of papers ...
Sergey Sedykh +3 more
openaire +4 more sources
Synthesis of Bispecific Conjugates by ADP‐Ribosyl Cyclases
Advanced Science, EarlyView.Genetic fusion of a CD38 enzymatic domain to antibody scaffolds allows site‐specific conjugation of small‐molecule ligands. Using this approach, a PSMA ligand DUPA is conjugated with an anti‐human CD3 Fab antibody. The resulting bispecific anti‐CD3‐DUPA conjugate facilitates recruitment and activation of cytotoxic T cells against PSMA‐expressing ...
Sunny H. Kim +8 more
wiley +1 more source
Fc Engineering for Developing Therapeutic Bispecific Antibodies and Novel Scaffolds [PDF]
, 2017 Therapeutic monoclonal antibodies have become molecules of choice to treat autoimmune disorders, inflammatory diseases, and cancer. Moreover, bispecific/multispecific antibodies that target more than one antigen or epitope on a target cell or recruit ...
Abhishek Saxena +3 more
core +1 more source
Blood-brain barrier transport kinetics of NOTA-modified proteins : the somatropin case [PDF]
, 2020 BACKGROUND: Chemical modifications such as PEG, polyamine and radiolabeling on proteins can alter their pharmacokinetic behaviour and their blood-brain barrier (BBB) transport characteristics. NOTA, i.e. 1,4,7-triazacyclononane-1,4,7-triacetic acid, is a
Bracke, Nathalie +7 more
core +1 more source
Advanced Science, EarlyView.Cytokine‐engineered CAR‐T cells represent a promising immunotherapy against malignancies due to direct tumor killing and potent immunity response. However, significant toxicities, including CRS and ICANS, have restricted clinical applications. How to keep the risk‐benefit balance of the advanced therapy is of great importance for maximizing the benefit
Xinru Zhang +7 more
wiley +1 more source
Site-specific PEGylation of an anti-CEA/CD3 bispecific antibody improves its antitumor efficacy
International Journal of Nanomedicine, 2018 Haitao Pan,1,2 Jiayu Liu,1,2 Wentong Deng,1,2 Jieyu Xing,1,2 Qing Li,1,2 Zhong Wang1,2 1School of Pharmaceutical Sciences, 2Centre for Cellular & Structural Biology, Sun Yat-Sen University, Guangzhou, People’s Republic of China Introduction ...
Pan H +5 more
doaj